-- Immunohistochemistry (IHC) feasibility study successfully completed using INOVIQ’s SubB2M probe to aid in diagnosis of malignant melanoma in tissue samples
-- Data from 144 tissue samples in this feasibility study demonstrated that SubB2M IHC detected melanoma with 91% sensitivity and discriminated between malignant melanoma and benign skin lesions
-- INOVIQ's SubB2M technology detects the pan-cancer biomarker Neu5Gc that is found at elevated levels in multiple human cancers
-- SubB2M-based IHC applications represent a new product opportunity for SubB2M as an IHC reagent in the $1.9b IHC market
-- INOVIQ to seek partners to sublicence the further development and commercialisation of SubB2M IHC tissue-based tests
For more information, download the attached PDF.
Download this document
